Last reviewed · How we verify
DFD06 Cream
DFD06 is a topical corticosteroid cream that reduces inflammation and immune-mediated skin responses by suppressing inflammatory cytokines and T-cell activation in dermatological conditions.
DFD06 is a topical corticosteroid cream that reduces inflammation and immune-mediated skin responses by suppressing inflammatory cytokines and T-cell activation in dermatological conditions. Used for Atopic dermatitis (eczema), Inflammatory dermatitis conditions.
At a glance
| Generic name | DFD06 Cream |
|---|---|
| Also known as | Clobetasol propionate Cream, 0.025%, clobetasol propionate, Impoyz Cream, Clobetasol Propionate 0.025% Cream |
| Sponsor | Promius Pharma, LLC |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
DFD06 is a potent topical corticosteroid formulation designed for enhanced skin penetration and efficacy in inflammatory dermatological conditions. It works by binding to glucocorticoid receptors in skin cells, suppressing the production of pro-inflammatory mediators and reducing immune cell infiltration. The cream formulation is optimized for improved bioavailability and therapeutic effect in treating moderate to severe dermatitis and related inflammatory skin disorders.
Approved indications
- Atopic dermatitis (eczema)
- Inflammatory dermatitis conditions
Common side effects
- Application site irritation
- Skin atrophy
- Folliculitis
Key clinical trials
- Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 (PHASE2)
- DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (PHASE2)
- A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFD06 Cream CI brief — competitive landscape report
- DFD06 Cream updates RSS · CI watch RSS
- Promius Pharma, LLC portfolio CI